BioStem Technologies, Inc. (BSEM)
3.76
-0.16
(-4.08%)
USD |
NASDAQ |
Aug 25, 09:45
BioStem Technologies Enterprise Value : 64.12M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 64.12M |
| August 21, 2026 | 57.35M |
| August 20, 2026 | 59.84M |
| August 19, 2026 | 53.87M |
| August 18, 2026 | 50.40M |
| August 17, 2026 | 47.73M |
| August 14, 2026 | 51.47M |
| August 13, 2026 | 49.51M |
| August 12, 2026 | 61.98M |
| August 11, 2026 | 58.60M |
| August 10, 2026 | 61.63M |
| August 07, 2026 | 67.20M |
| August 06, 2026 | 65.90M |
| August 05, 2026 | 53.68M |
| August 04, 2026 | 52.33M |
| August 03, 2026 | 49.86M |
| July 31, 2026 | 53.32M |
| July 30, 2026 | 51.46M |
| July 29, 2026 | 52.89M |
| July 28, 2026 | 53.98M |
| July 27, 2026 | 62.34M |
| July 24, 2026 | 65.73M |
| July 23, 2026 | 62.59M |
| July 22, 2026 | 64.30M |
| July 21, 2026 | 65.19M |
| Date | Value |
|---|---|
| July 20, 2026 | 63.59M |
| July 17, 2026 | 61.45M |
| July 16, 2026 | 61.07M |
| July 15, 2026 | 62.14M |
| July 14, 2026 | 61.98M |
| July 13, 2026 | 64.76M |
| July 10, 2026 | 60.02M |
| July 09, 2026 | 51.58M |
| July 08, 2026 | 52.36M |
| July 07, 2026 | 52.80M |
| July 06, 2026 | 59.49M |
| July 02, 2026 | 52.00M |
| July 01, 2026 | 51.65M |
| June 30, 2026 | 53.07M |
| June 29, 2026 | 48.62M |
| June 26, 2026 | 50.40M |
| June 25, 2026 | 47.94M |
| June 24, 2026 | 53.03M |
| June 23, 2026 | 52.35M |
| June 22, 2026 | 55.60M |
| June 18, 2026 | 57.44M |
| June 17, 2026 | 56.00M |
| June 16, 2026 | 60.04M |
| June 15, 2026 | 59.05M |
| June 12, 2026 | 58.80M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -37.75M |
| CorMedix, Inc. | 530.88M |
| Eloxx Pharmaceuticals, Inc. | 18.72M |
| Cannabis Global, Inc. | -- |
| Breakthrough Chemistry, Inc. | 1.389M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.971M |
| Revenue (Quarterly) | 7.899M |
| Total Expenses (Quarterly) | 16.87M |
| EPS Diluted (Quarterly) | -0.5178 |
| Gross Profit Margin (Quarterly) | 52.55% |
| Profit Margin (Quarterly) | -113.6% |
| Earnings Yield | -44.64% |
| Normalized Earnings Yield | -44.64 |